CoChat
Sign Up
Cited by 171Vitamin D Research StudiesTreatment of Major DepressionFatty Acid Research and Health

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Effect of Long-term Vitamin D 3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial

Open access
Okereke, Olivia I., Reynolds, Charles F., Mischoulon, David, Chang, Grace, Vyas, Chirag M., Cook, Nancy R., Weinberg, Alison, Bubes, Vadim, Copeland, Trisha, Friedenberg, Georgina, Lee, I-Min, Buring, Julie E., Manson, JoAnn E.·2020·JAMA
DOI 10.1001/jama.2020.10224PMC PMC7403921
Open this paper in CoChat — free accountOpen PDF

Abstract

Importance: Low levels of 25-hydroxyvitamin D have been associated with higher risk for depression later in life, but there have been few long-term, high-dose large-scale trials. Objective: To test the effects of vitamin D3 supplementation on late-life depression risk and mood scores. Design, Setting, and Participants: There were 18 353 men and women aged 50 years or older in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized clinical trial of cardiovascular disease and cancer prevention among 25 871 adults in the US. There were 16 657 at risk for incident depression (ie, no depression history) and 1696 at risk for recurrent depression (ie, depression history but no treatment for depression within the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017, and this was the final date of follow-up. Intervention: Randomized assignment in a 2 × 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were randomized to vitamin D3 and 9172 were randomized to matching placebo. Main Outcomes and Measures: The primary outcomes were the risk of depression or clinically relevant depressive symptoms (total of incident and recurrent cases) and the mean difference in mood scores (8-item Patient Health Questionnaire depression scale [PHQ-8]; score range, 0 points [least symptoms] to 24 points [most symptoms]; the minimal clinically important difference for change in scores was 0.5 points). Results: Among the 18 353 randomized participants (mean age, 67.5 [SD, 7.1] years; 49.2% women), the median treatment duration was 5.3 years and 90.5% completed the trial (93.5% among those alive at the end of the trial). Risk of depression or clinically relevant depressive symptoms was not significantly different between the vitamin D3 group (609 depression or clinically relevant depressive symptom events; 12.9/1000 person-years) and the placebo group (625 depression or clinically relevant depressive symptom events; 13.3/1000 person-years) (hazard ratio, 0.97 [95% CI, 0.87 to 1.09]; P = .62); there were no significant differences between groups in depression incidence or recurrence. No significant differences were observed between treatment groups for change in mood scores over time; mean change in PHQ-8 score was not significantly different from zero (mean difference for change in mood scores, 0.01 points [95% CI, -0.04 to 0.05 points]). Conclusions and Relevance: Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with vitamin D3 compared with placebo did not result in a statistically significant difference in the incidence and recurrence of depression or clinically relevant depressive symptoms or for change in mood scores over a median follow-up of 5.3 years. These findings do not support the use of vitamin D3 in adults to prevent depression. Trial Registration: ClinicalTrials.gov Identifiers: NCT01169259 and NCT01696435.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2020.10224

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 171

Related

See all

Metadata

Authors
Okereke, O. I., Reynolds, C. F., Mischoulon, D., Chang, G., Vyas, C. M., Cook, N. R., Weinberg, A., Bubes, V., Copeland, T., Friedenberg, G., Lee, I.-M., Buring, J. E., & Manson, J. E.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Pittsburgh (US)
  • Harvard University (US)
  • VA Boston Healthcare System (US)
Corresponding author
Okereke, Olivia I.
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2020-08-04
Volume
324
Issue
5
Pages
471
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2020.10224
PMC
PMC7403921
OpenAlex
W3047395496
Cited by
171
References
31
Citations by year
2026: 26 · 2025: 19 · 2024: 28 · 2023: 30 · 2022: 26 · 2021: 28 · 2020: 13
FWCI
15.93
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (R01AG036755)
  • National Heart, Lung, and Blood Institute (R01HL102122, R01HL101932)
  • National Institute of Mental Health (P30MH090333, R01MH091448)
  • National Cancer Institute (U01CA138962, R01CA138962)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK088078, R01DK088762)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060574, R01AR059086)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
vitamin D3 supplementation, vitamin D3, depression, depressive symptoms, mood, geriatric depression, 25-hydroxyvitamin D, fish oil, omega-3 fatty acids, older adults, PHQ-8, depression prevention, VITAL trial, ancillary studies, cardiovascular disease prevention, cancer prevention
MeSH terms
Affect, Aged, Cholecalciferol, Depression, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Surveys and Questionnaires, Recurrence, Vitamins, Incidence, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review